Published in Clin Exp Immunol on August 01, 1992
Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology (1993) 0.96
Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology (1995) 0.86
Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. Immunology (1994) 0.81
Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transpl Immunol (1993) 0.79
Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. Clin Exp Immunol (1993) 0.78
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 15.76
The mechanism of action of cyclosporin A and FK506. Immunol Today (1992) 7.57
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07
Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science (1991) 6.80
Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature (1991) 6.30
The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol (1989) 4.30
Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol (1990) 3.29
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet (1992) 2.06
RS-61443--a phase I clinical trial and pilot rescue study. Transplantation (1992) 1.97
Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol (1991) 1.67
RS-61443--a new, potent immunosuppressive agent. Transplantation (1991) 1.57
Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest (1991) 1.55
Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med (1991) 1.48
The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation (1992) 1.23
Cyclosporin: use outside transplantation. BMJ (1991) 1.22
FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. Transplant Proc (1991) 1.15
Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol (1992) 1.14
Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation (1991) 1.13
Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol (1991) 1.12
Immunophilin-ligand complexes as probes of intracellular signaling pathways. Transplant Proc (1991) 1.05
Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation (1991) 0.96
FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. J Immunol (1991) 0.93
Facilitation of specific tolerance induction in adult mice by RS-61443. Transplantation (1992) 0.89
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. Transplant Proc (1991) 0.87
Pharmacology of cyclosporine (sandimmune). V. Pharmacological effects on immune function: in vitro studies. Pharmacol Rev (1990) 0.86
Comparative activity of CP-17,193 and five established immunosuppressives toward the antigens SRBC and EL4. Clin Exp Immunol (1981) 0.84
Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation (1991) 0.83
Advantages of mizoribine over azathioprine in combination therapy with cyclosporine for renal transplantation. Transplant Proc (1990) 0.82
A new triple-drug induction therapy with low dose cyclosporine, mizoribine and prednisolone in renal transplantation. Transplant Proc (1989) 0.82
The effects of CP 17193, an immunosuppressive pyrazaloquinoline, on the development of spontaneous lupus disease in NZBW F1 hybrid mice. Clin Exp Immunol (1992) 0.82
Markedly enhanced therapeutic effect of deoxyspergualin on acute rejection when combined with methylprednisolone in kidney recipients. Transplant Proc (1991) 0.80
Clinical application of 15-deoxyspergualin for treatment of acute graft rejection following renal transplantation. Transplant Proc (1990) 0.78
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
FK 506: an immunosuppressant for the 1990s? Lancet (1991) 2.80
Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol (1999) 2.48
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
FK-506--how much potential? Immunol Today (1989) 2.20
Cyclosporin A inhibits lymphokine production but not the responses of macrophages to lymphokines. Immunology (1983) 1.99
Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol (2001) 1.95
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation (1996) 1.65
Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation (1995) 1.63
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol (2000) 1.60
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol (1996) 1.53
Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation (1995) 1.51
Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood (2001) 1.47
Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo. J Immunol (2000) 1.47
Pregnancy specific beta1-glycoprotein--a product of the syncytiotrophoblast. Experientia (1976) 1.46
Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal. Transplantation (1981) 1.38
Toxicity of the immune suppressant cyclosporin A in the rat. J Pathol (1982) 1.38
Immunobiology of cyclosporin A--a review. Aust J Exp Biol Med Sci (1983) 1.31
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc (1994) 1.29
Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea-pigs. Immunology (1983) 1.27
Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol (1994) 1.25
Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells. Am J Transplant (2006) 1.24
Fundamental Ca2+ signaling mechanisms in mouse dendritic cells: CRAC is the major Ca2+ entry pathway. J Immunol (2001) 1.23
Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. Transplantation (1998) 1.22
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Cyclosporin: use outside transplantation. BMJ (1991) 1.22
Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol (2001) 1.21
Evaluation of carrageenan as an immunosuppressive agent and mediator of intravascular coagulation. Biomedicine (1976) 1.20
Dendritic cells and immune regulation in the liver. Gut (2003) 1.19
Biological and clinical significance of pregnancy-associated alpha2-glycorprotein (alpha/-PAG)-a review. Invest Cell Pathol (1981) 1.18
Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release (2008) 1.17
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation (1997) 1.17
Generation of DC from mouse spleen cell cultures in response to GM-CSF: immunophenotypic and functional analyses. Immunology (1995) 1.17
Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol (1997) 1.16
Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells. Transplantation (1994) 1.16
New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant (2008) 1.14
Cyclosporine: immunology, toxicity and pharmacology in experimental animals. Agents Actions (1984) 1.14
Experimental cyclosporin A nephrotoxicity. Br J Exp Pathol (1982) 1.12
Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. Clin Exp Immunol (1990) 1.11
Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther (2000) 1.10
Cyclosporine-induced fetotoxicity in the rat. Transplantation (1985) 1.10
Cytokine mRNA profiles in mouse orthotopic liver transplantation. Graft rejection is associated with augmented TH1 function. Transplantation (1995) 1.10
Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant (2008) 1.10
Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation (2001) 1.09
Toxicity of various carrageenans in the mouse. Br J Exp Pathol (1976) 1.09
Major histocompatibility complex class II antigen (HLA-DR, DQ and DP) expression in human fetal skin. Tissue Antigens (1986) 1.09
FK 506 inhibition of cyclosporine metabolism by human liver microsomes. Transplant Proc (1991) 1.09
Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol (2001) 1.08
Effect of carrageenan on activity of the mononuclear phagocyte system in the mouse. Br J Exp Pathol (1978) 1.07
Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol (1998) 1.07
Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin Exp Immunol (1991) 1.07
Phenotypic and functional characterization of mouse hepatic CD8 alpha+ lymphoid-related dendritic cells. J Immunol (2000) 1.07
Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol (1997) 1.05
Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation (1999) 1.05
Serum cyclosporin levels, hepatic drug metabolism and renal tubulotoxicity. Biochem Pharmacol (1984) 1.03
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. Immunology (1990) 1.03
FK-506 enters the clinic. Immunol Today (1990) 1.03
Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation (1998) 1.01
Acetone production by methylobacteria. Arch Microbiol (1976) 0.99
Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol (1988) 0.99
Fc receptor-bearing and phagocytic cells in syngeneic tumours of C. parvum- and carrageenan-treated mice. Br J Cancer (1979) 0.98
Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. Transplantation (1989) 0.98
Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse. Clin Exp Immunol (1983) 0.98
Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation (1998) 0.97
Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology (1988) 0.97
The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production. Transplantation (1993) 0.97
Cyclosporin A prevents suppression of delayed-type hypersensitivity in mice immunized with high-dose sheep erythrocytes. Immunology (1987) 0.97
Potentiation of tumour growth by carrageenan. Transplantation (1977) 0.97
Dendritic cells and tolerance induction. Clin Exp Immunol (1996) 0.97
Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation (1996) 0.96
Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance. J Immunol (2001) 0.96
Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. Transplant Proc (1992) 0.96
In vivo administration of flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J Immunol (1997) 0.96
Nitric oxide production by mouse bone marrow-derived dendritic cells: implications for the regulation of allogeneic T cell responses. Transplantation (1996) 0.96
Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc (1998) 0.95
A toxicological study in rats receiving immunotherapeutic doses of cyclosporin A. Transplantation (1981) 0.95
Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour. Immunology (1986) 0.95
Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. Transplant Proc (1991) 0.95
Detection of pregnancy associated alpha 2-glycoprotein (alpha 2-PAG), an immunosuppressive agent, in IgA producing plasma cells and in body secretions. Clin Exp Immunol (1983) 0.94
Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks. Br J Exp Pathol (1983) 0.94
Rosette inhibition levels during early human gestation. J Reprod Immunol (1980) 0.94
Potential of tolerogenic dendritic cells for transplantation. Semin Immunol (2001) 0.93
Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival. Transplant Proc (1999) 0.93
Effects of the antiprotease Trasylol on peripheral blood leucocytes. Experientia (1978) 0.93
The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. Scand J Immunol (1990) 0.92
Study of pregnancy-associated alpha2-glycoprotein in relation to populations of human blood leucocytes. Int Arch Allergy Appl Immunol (1979) 0.92
Histological and ultrastructural changes following carrageenan injection in the mouse. J Pathol (1980) 0.92
Preferential induction of Th1 responses by functionally mature hepatic (CD8alpha- and CD8alpha+) dendritic cells: association with conversion from liver transplant tolerance to acute rejection. Transplantation (2000) 0.92
Carrageenan: a review of its effects on the immune system. Agents Actions (1981) 0.92
EAU in the guinea pig: inhibition of cell-mediated immunity and Ia antigen expression by cyclosporin A. Clin Exp Immunol (1987) 0.91
Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Gene Ther (1999) 0.90
Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol (2003) 0.90